Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Telomir Pharmaceuticals, Inc. Common Stock

Healthcare US TELO

1.25USD
-0.03(2.34%)

Last update at 2026-06-23T20:03:00Z

Day Range

1.251.30
LowHigh

52 Week Range

4.7611.90
LowHigh

Fundamentals

  • Previous Close 1.28
  • Market Cap0.00000M
  • Volume82114
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30
Income before tax -13.07186M -0.85415M -0.13813M
Minority interest - - -
Net income -13.07186M -0.85415M -0.13813M
Selling general administrative 0.60M 0.02M 0.01M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation - - -
Ebit - - -
Ebitda - - -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -3.94205M -0.85415M -0.13813M
Other operating expenses - - -
Interest expense 1.64M 0.00000M -
Tax provision - - -
Interest income - - -
Net interest income -1.64305M 0.00000M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 3.94M 0.85M 0.14M
Cost of revenue - - -
Total other income expense net -7.48677M - -
Discontinued operations - - -
Net income from continuing ops -13.07186M -0.85415M -0.13813M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30
Total assets 4.77M 0.05M 0.00000M
Intangible assets - - -
Earning assets - - -
Other current assets - - -
Total liab 1.34M 0.99M 0.14M
Total stockholder equity 3.44M -0.93728M -0.13813M
Deferred long term liab - - -
Other current liab - - -
Common stock - - -
Capital stock 0.00000M 0.00000M 0.00000M
Retained earnings -14.06414M -0.99228M -0.13813M
Other liab - - -
Good will - - -
Other assets - - -
Cash 0.00123M 0.00142M 0.00000M
Cash and equivalents - - -
Total current liabilities 1.34M 0.99M 0.14M
Current deferred revenue - - -
Net debt 0.10M - -
Short term debt - - -
Short long term debt 0.10M - -
Short long term debt total - - -
Other stockholder equity - - -
Property plant equipment - - -
Total current assets 0.44M 0.05M 0.00000M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables - - -
Long term debt - - -
Inventory - - -
Accounts payable 0.71M 0.40M 0.02M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 4.34M 0.00000M 0.00000M
Capital lease obligations - - -
Long term debt total - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30
Investments - - -
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities 3.86M 0.47M 0.12M
Change to operating activities - - -
Net income -13.07186M -0.85415M -0.13813M
Change in cash -0.00019M 0.00142M 0.00000M
Begin period cash flow 0.00142M 0.00000M 0.00000M
End period cash flow 0.00123M 0.00142M 0.00000M
Total cash from operating activities -3.85980M -0.46866M -0.11940M
Issuance of capital stock 1.00M 0.06M 0.00000M
Depreciation - - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities - - -
Change to netincome - - -
Capital expenditures 0.00000M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.11M 0.39M 0.02M
Stock based compensation - - -
Other non cash items 1.61M - -
Free cash flow -3.85980M -0.46866M -0.11940M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
TELO
Telomir Pharmaceuticals, Inc. Common Stock		 -0.03 2.34% 1.25 - - - -
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Telomir Pharmaceuticals, Inc. Common Stock

855 N Wolfe Street, Baltimore, MD, United States, 21205

Key Executives

Name Title Year Born
Dr. Christopher C. Chapman Jr., M.D. Co-Founder, Chairman & CEO 1953
Mr. Nathen Fuentes CPA CFO, Treasurer, & Secretary 1983
Mr. Christos Nicholoudis Esq. General Counsel & Director 1991

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions